Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study

► Neurocognitive impairment is a central clinical feature of schizophrenia. ► Cognitive impairment in schizophrenia is an important target for treatments. ► Typical and atypical antipsychotics may improve cognitive impairment in schizophrenia. ► Cognitive improvement with typical and atypical antipsychotics may be small. ► Atypical antipsychotics may be superior to typical ones in some cognitive domains.